Evidence map›Paper›PMID 42572660›Full record

ReviewRomanian journal of ophthalmology

Optical Coherence Tomography Angiography in Age-Related Macular Degeneration.

Alexandru-Ionut Duculescu, Ruxandra Pirvulescu, Aida Geamanu, Eylul Firinciogullari, Eduard Toma, Cristina Alexandrescu, Horia Tudor Stanca

Abstract readReview
In one paragraph

Review in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexandru-Ionut Duculescu"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Ruxandra Pirvulescu"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Aida Geamanu"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Eylul Firinciogullari"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Eduard Toma"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Cristina Alexandrescu"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Horia Tudor Stanca"Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To review and synthesize current evidence regarding the importance of optical coherence tomography angiography (OCTA) in the assessment of choriocapillaris alterations and macular neovascularization (MNV) across the spectrum of age-related macular degeneration (AMD), focusing on disease progression and clinical implications. Methods: Selective review of the specialized literature, concentrating on both qualitative and quantitative OCTA analyses of the retinal and choroidal microvasculature in AMD. We focused on measures related to choriocapillaris flow deficits, the morphology and maturity of MNV, and their associations with structural changes like drusen, geographic atrophy, and exudative conditions. The review included findings from both spectral-domain and swept-source OCTA systems. Results: OCTA enables non-invasive, depth-resolved visualization of choriocapillaris and MNV alterations throughout the progression of AMD. In the early and intermediate stages of AMD, localized choriocapillaris flow deficits are often observed beneath drusen and around lesion areas. In more advanced stages, there is significant choriocapillaris damage, especially near geographic atrophy and macular neovascularization. Quantitative OCTA biomarkers, such as density and flow deficit percentage, show strong correlations with disease stage, progression risk, and treatment response. Additionally, the maturity patterns of MNV identified through OCTA seem to affect the integrity of the surrounding choriocapillaris and the dynamics of atrophy. Discussion: The reviewed studies support a close relationship between choriocapillaris dysfunction, the development of macular neovascularization, and the progression of AMD. These findings reinforce the concept that vascular alterations play a central role throughout the disease spectrum and highlight the potential of OCTA to provide biomarkers that may improve prognostic assessment and treatment monitoring. However, further standardization of imaging protocols and quantitative analysis methods is needed before these biomarkers can be fully integrated into routine clinical practice. Conclusions: OCTA has become a crucial imaging tool for understanding microvascular changes in AMD. The quantitative evaluation of the choriocapillaris and detailed analysis of MNV morphology offer important insights into disease mechanisms, progression risk, and treatment monitoring. Incorporating OCTA-derived biomarkers into routine clinical practice could improve personalized management strategies for patients across the spectrum of AMD.

Indexed as

ChoroidFluorescein AngiographyMacular DegenerationRetinal VesselsTomography, Optical CoherenceDisease ProgressionFundus OculiHumansage-related macular degenerationAMD = Age-related macular degenerationchoriocapillarisCNV = choroidal neovascularizationCVD = choriocapillaris vascular densityGA = geographic atrophygeographic atrophymacular neovascularizationMNV = macular neovascularizationnAMD = neovascular AMDOCTA = optical coherence tomography angiographyOCT = optical coherence tomographyODS = optical coherence tomography-reflective drusen substructuresoptical coherence tomography angiographyRPE = retinal pigment epitheliumSD-OCTA = spectral-domain OCTASS-OCTA = swept source OCTAVEGF = vascular endothelial growth factor

Identifiers

PMID42572660
PMCPMC13453101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.